Tough Tortoise of a Drug Beating Metastatic Pancreatic Cancer
Rexahn Pharmaceuticals is testing RX-3117, a slow-releasing drug similar to gemcitabine, in a clinical trial for metastatic pancreatic cancer patients.
A Combination of Neoadjuvant Chemotherapy and Radiation Shows Promise
Dr. Alok Khorana discusses the results of clinical trials of neoadjuvant chemotherapy and radiation to make surgery more effective.
Adjuvant Chemotherapy with Modified FOLFIRINOX Regimen Improves Survival
A French clinical trial showed that adjuvant chemotherapy (given after surgery) with modified FOLFIRINOX improves survival of pancreatic cancer patients.
A Potential Role for PARP Inhibitors in Pancreatic Cancer
Due to numerous factors, including rising rates of obesity and smoking, for example, pancreatic cancer jumped to number three, and…
Multicenter Trial Focuses on Neoadjuvant Treatment for Borderline Resectable and Locally Advanced Disease
Dr. David Ryan outlines a new trial for pre-surgical pancreatic cancer treatment combining a blood pressure drug, immunotherapy, standard care and SBRT.
Collaborative Multi-Center Immunotherapy Trial Targets CD40 and PD-1
Dr. Mark O’Hara outlines a collaborative clinical trial of two immunotherapy agents–a checkpoint inhibitor and a monoclonal antibody–plus standard chemotherapy.
Targeting Cancer Metabolism
Researchers from Tyme Technologies are focusing on cancer cell metabolism, particularly tyrosine, as a way to kill cancer cells.
Precision Medicine from the Get-Go for Pancreatic Cancer
Dr. Ben George and colleagues at the Medical College of Wisconsin are using molecular profiling to determine the best chemotherapy for a patient’s pancreatic cancer.
A Simple Blood Test for Early Detection of Eight Cancers Shows Promise
Dr. Anne Marie Lennon explains the CancerSEEK blood test, a liquid biopsy in clinical trials for early detection of eight cancers, including pancreatic.
Standard of Care Plus
Dr. Allyson Ocean explains why pancreatic cancer patients should consider clinical trials, which go beyond standard of care.